Kidney cancer is a type of cancer which starts in kidney cells. Two major types of kidney cancer include transitional cell carcinoma (TCC) and renal cell carcinoma (RCC). Different types of kidney cancer get developed in different ways which imply different long-term outcomes. This cancer originates in two principal locations of the kidney – the renal pelvis and the renal tubule.
A new report published by Fact.MR estimates the global kidney cancer diagnostics market to exhibit an impressive expansion at during the forecast period 2017 to 2022. In terms of revenues, the global market for kidney cancer diagnostics will reach nearly US$ 700 Mn by 2022-end.
Targeted Systemic Therapies for Metastatic Kidney Cancer are Providing Significant Benefits to Survival and Progression
Over the past few years, the diagnosis and management of kidney cancer, or, renal cell carcinoma (RCC), have undergone tremendous transformations. A number of discoveries, studies, and trails are being taken in renal mass biopsy, minimally-invasive thermal ablation, and active surveillance, owing to the surge in diagnosis rate of small renal masses, usually in patients with high morbidity risks related to operative treatment. In addition, targeted systemic therapies associated with metastatic kidney cancer have replaced cytokine-based treatment, providing significant benefits to survival and progression. Recent trails and reviews have cemented the partial nephrectomy’s role as the standard diagnosis-based surgical management option for majority of low-stage masses, and roles of adrenalectomy and lymphadenectomy pertaining to nephrectomy. These incidences are estimated to augment growth of the global kidney cancer diagnostics market.
Kidney cancer has been witnessed to occur majorly in older population. Diagnosis of kidney cancer becomes an intricate task, considering the condition of geriatric patients. While staple diagnostic technologies such as MRI and CT scan continue to play a pivotal role in the global market, patients are also expecting the emergence of all-inclusive diagnosis tests. Medical organizations are also funneling high investments in R&D of kidney cancer diagnostics, particularly to improve the precision of early stage diagnosis tests. Through advancements in medical technology, the global market for kidney cancer diagnostics is also expected to witness emergence of new tests that can simultaneously decelerate the pace of tumor maturation between multiple stages of kidney cancer.
Market Taxonomy
|
Test Type |
End User |
Indication |
|
Immunohistochemistry |
Hospital Associated Labs |
Renal Cell Carcinoma |
|
Urine Analysis |
Independent Diagnostic Laboratories |
Transitional Cell Carcinoma |
|
Complete Blood Count |
Cancer Research Institutes |
Wilms Tumor |
|
Blood Chemistry Test |
Others |
Kidney Lymphoma |
|
Kidney Sarcoma |
(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)
Hospital-associated Labs will Remain Preferred for Kidney Cancer Diagnostics
On the basis of end-users, hospital-associated labs are estimated to remain preferred for kidney cancer diagnostics, accounting for the largest revenues by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global kidney cancer diagnostics market. In addition, cancer research institutes are expected to register the highest CAGR in the market through 2022.
Immunochemistry tests will continue to be sought-after for kidney cancer diagnostics, with revenues expected to reach US$ 351.8 Mn by 2022-end. This test type segment is projected to register the highest CAGR in the market through 2022, followed by complete blood count test.
Urine analysis will remain the second largest adopted tests for kidney cancer diagnostics across the globe. However, revenues from blood chemistry tests of kidney cancer diagnostics will continue to be lower as compared to rest of the test segments in the market.
North America to Remain the Largest Market for Kidney Cancer Diagnostics
In terms of revenues, North America is expected to remain the largest market for kidney cancer diagnostics, followed by Europe. However, kidney cancer diagnostics market in Europe will exhibit a comparatively higher CAGR than North America during the forecast period. In addition, Asia Pacific excluding Japan (APEJ) will continue to be the fastest expanding market for kidney cancer diagnostics through 2022.
Competition Tracking
Myriad Genetics Inc, NeoGenomics Laboratories, NanoString Technologies Inc., Sysmex Corporation, Rosetta Genomics, Illumina, Inc., Quest Diagnostics Incorporated, Roche Holding AG, Thermo Fisher Scientific Inc., and Abbott Laboratories are observed as key players in the global market for kidney cancer diagnostics.
Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR
Kidney cancer has been observed to occur mostly in geriatric population. The targeted therapies have been aiding the kidney cancer treatment in the recent past. Researchers have developed various new class of novel drugs, which enable blocking of the kidney cancer’s molecular driver, also called clear cell renal cell carcinoma (ccRCC).
Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for kidney cancer. Rising number of deaths caused by kidney cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of kidney cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo. The burden of controlling the incidence of kidney cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.
The report on the global kidney cancer diagnostics market discusses such key factors that govern the economics of kidney cancer diagnostics across the globe. Some of the key influences for the growth of global kidney cancer diagnostics market include:
- rising presence of carcinogenic elements in common consumables
- surging exposure to toxic substances in factories & industrial settings
- lack of awareness related to causes, symptoms, and preventive measures for kidney cancer
- high healthcare costs, deterring kidney cancer patients from seeking optimum diagnosis
With growing incidence of kidney cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for kidney cancer. As kidney cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of kidney cancer.
Need for Premeditated Kidney Cancer Patient Compliance
Kidney cancer patients are often riddled with confusing options for diagnosis. Choosing the right screening test can become a dilemma for the patient and his/her family. Companies manufacturing medical instruments and devices for diagnosis of kidney cancer are expected to mitigate such difficulties by facilitating a well-laid patient compliance regime.
The global market for kidney cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of kidney cancer patients.
Key players in the global kidney cancer diagnostics market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on kidney cancer patients. Such cooperative efforts are of paramount importance in the global kidney cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.
Kidney Cancer diagnostics market – Regional Overview & Competitive Backdrop
A comprehensive section on the regional analysis of global kidney cancer diagnostics market is included in the report. North America, Europe, Japan, Asia-Pacific excluding Japan (APEJ), Latin America, and Middle East & Africa are key regions into which the expansion of global kidney cancer diagnostics market is studied. Developed markets with robust healthcare infrastructures are deemed lucrative for patients seeking diagnosis for kidney cancer. On the other hand, higher resource availability, cheap wages, and lenient manufacturing regulations in developing regions attract the attention of manufacturers of kidney cancer diagnosis instruments.
In the report, there is an elaborate section on the competitive landscape of global kidney cancer diagnostics market. This part profiles key players in the global market, which includes leading manufacturers of diagnostic devices and related medical apparatus. The scalability employed in profiling these players includes criteria such as the company’s contribution to global kidney cancer diagnostics market revenues, recent mergers & acquisitions involving the company, and new product launches. Through this report, companies can also understand the investment standpoint in the global kidney cancer diagnostics market, which can be further inferred while taking insightful actions.
Research Methodology
Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,
- Primary research
- Secondary research
- Trade research
- Focused interviews
- Social media analysis
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Our Clients
Kidney Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022